Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 120 mg - capsule, modified release - excipient ingredients: iron oxide yellow; sodium lauryl sulfate; purified talc; titanium dioxide; magnesium stearate; gelatin; indigo carmine; iron oxide black; macrogol 6000; hydrogenated vegetable oil; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; industrial methylated spirit; shellac; sulfuric acid; ammonia - ms mono capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms mono capsules are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms mono capsules are not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - morphine sulfate pentahydrate, quantity: 10 mg - capsule, modified release - excipient ingredients: purified talc; purified water; maize starch; gelatin; sucrose; methacrylic acid copolymer; ethylcellulose; hypromellose; macrogol 6000; diethyl phthalate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - management of severe pain kapanol 10, 20, 50 and 100 mg capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. kapanol is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. kapanol is not indicated as an as-needed (prn) analgesia.,symptom reduction of chronic breathlessness kapanol 10 and 20 mg capsules are indicated for the symptomatic reduction of chronic breathlessness in the palliative care of patients with distressing breathlessness due to severe copd, cardiac failure, malignancy or other cause. kapanol should only be used after treatments for the underlying cause(s) of the breathlessness have been optimised and nonpharmacological treatments are not effective. treatment with kapanol in this setting should only be initiated by a specialist knowledgeable in its use.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - morphine sulfate pentahydrate, quantity: 50 mg - capsule, modified release - excipient ingredients: hypromellose; methacrylic acid copolymer; gelatin; sucrose; purified talc; maize starch; purified water; ethylcellulose; diethyl phthalate; macrogol 6000; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - management of severe pain kapanol 10, 20, 50 and 100 mg capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. kapanol is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. kapanol is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - morphine sulfate pentahydrate, quantity: 20 mg - capsule, modified release - excipient ingredients: methacrylic acid copolymer; macrogol 6000; gelatin; purified water; diethyl phthalate; sucrose; ethylcellulose; maize starch; hypromellose; purified talc; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - management of severe pain: kapanol 10, 20, 50 and 100 mg capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. kapanol is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. kapanol is not indicated as an as-needed (prn) analgesia.,symptom reduction of chronic breathlessness: kapanol 10 and 20 mg capsules are indicated for the symptomatic reduction of chronic breathlessness in the palliative care of patients with distressing breathlessness due to severe copd, cardiac failure, malignancy or other cause. kapanol should only be used after treatments for the underlying cause(s) of the breathlessness have been optimised and nonpharmacological treatments are not effective. treatment with kapanol in this setting should only be initiated by a specialist knowledgeable in its use.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 60 mg - tablet, modified release - excipient ingredients: lactose; hyetellose; cetostearyl alcohol; magnesium stearate; purified talc; titanium dioxide; hypromellose; sunset yellow fcf; quinoline yellow; erythrosine; macrogol 400 - ms contin is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms contin is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms contin is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 30 mg - tablet, modified release - excipient ingredients: lactose; hyetellose; cetostearyl alcohol; magnesium stearate; purified talc; titanium dioxide; indigo carmine; hypromellose; sunset yellow fcf; erythrosine; macrogol 400 - ms contin is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms contin is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms contin is not indicated as an as-needed (prn) analgesia.